79 results about "Hiv disease" patented technology

This invention provides a method for synthesizing the anti-AIDS drug enovirine. This invention belongs to the field of pharmaceutical preparation technology. The synthesis method includes the following steps: (1) SM1 compound reacts with Grignard reagent and then reacts with SM2 compound to obtain compound III; (2) Compound III undergoes oxidation reaction to obtain compound II; (3) Compound II undergoes demethylation reaction under the action of demethylation reagent to obtain compound I; (4) Compound I undergoes ethylation reaction to obtain enovirine. The synthesis route of this invention effectively avoids the use of highly toxic cyanide reagents and expensive heavy metal catalysts. At the same time, the reaction conditions of this route are simple and mild, with high yield, and have excellent industrialization prospects.

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The application discloses a kind of diaromatic pyrimidine compounds containing fused heterocycle and preparation method and application thereof.The compound has the structure shown in general formula I.The application further relates to pharmaceutical compositions containing the compound of formula I.Active screening experiments show that the compound of the application has good anti-HIV and CHIKV activity, and therefore the application further provides the use of the above-mentioned compound in the preparation of anti-AIDS drugs and anti-Chikungunya virus drugs.

The invention discloses application of a gp130 inhibitor in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. Experiments prove that combination of IL-6 family cell factors and a gp130 receptor is inhibited, so that downward signal transmission of a JAK2 / STAT3 signal channel triggered by the IL-6 family cell factors is inhibited, the purposes of inhibiting cell fusion induced by SARS-CoV-2 spike protein and further influencing replication and propagation of SARS-CoV-2 are achieved, and a small-molecule inhibitor SC144 is an inhibitor of gp130, has a remarkable effect of inhibiting SARS-CoV-2 virus replication and has a good application prospect. Meanwhile, the traditional Chinese medicine composition also has a remarkable effect of inhibiting replication of viruses such as human immunodeficiency virus, herpes simplex virus and respiratory syncytial virus.

A compound of formula I or a stereoisomer, isotopic isomer, tautomer or pharmaceutically acceptable salt thereof: wherein a ligand that binds to Nef protein (NB) is covalently linked to a ligand that binds to E3 ligase cerebron (CB) via a linker (L).

The invention discloses an AIDS (acquired immune deficiency syndrome) short-term amplification prediction and early warning method and device, electronic equipment and a medium, which are used for solving the problem of how to effectively predict the short-term growth trend of AIDS cases in a region and give an early warning in time under the conditions of short data time span and sparse data. Acquiring newly added data and public attention data of the AIDS cases in the preset time window up to the month in the to-be-detected area; wherein the to-be-detected area comprises a plurality of sub-areas; inputting the newly added data of the AIDS cases and the public attention data into a short-term amplification prediction model for binary pre-training based on a unified large model framework and joint parameter fine tuning, and outputting prediction probabilities of reaching the preset AIDS case amplification in the next month of each sub-region through binary prediction; and for each sub-region, when the prediction probability indicates that the number of newly added AIDS cases in the next month of the sub-region meets a preset AIDS case amplification early warning condition, generating an early warning suggestion of the sub-region.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The present invention relates to the technical field of drug for treatment of AIDS. Disclosed are a polycyclic carbamoyl pyridone derivative, a preparation method therefor, and pharmaceutical composition thereof. The derivative comprises the compound represented by formula (I)-1 or formula (I)-2, or an isomer, pharmaceutically acceptable salt, hydrate or solvate thereof. At least one group of functional groups in (1)-(3) below and a ring A form a spirolcycle or spiroheterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; the polycyclic carbamoyl pyridone derivative can selectively inhibit the activity of HIV integrase, and thus can be used for preventing and treating AIDS.

A production device, method and application of nano-sized zinc molybdate. The device includes a double-cone mixer; an elevator is obliquely provided at a bottom of a discharge port of the double-cone mixer; a rear end of the elevator is located above a feeder; the feeder is connected to one end of an electric heating converter, an other end of the electric heating converter is connected to a finished product bin; a top of the finished product bin is provided with an atomizing nozzle for adding nanomaterial dispersant; the atomizing nozzle is connected to a syringe pump by pipeline. High-purity nano-sized molybdenum trioxide and nano-sized zinc oxide are adopted to synthesize nano-sized zinc molybdate in an electric heating converter. The nano-sized zinc molybdate prepared by the device and method can be used for treatment of African swine fever virus, coronavirus, and AIDS phase I, Ebola, dengue fever, polio viruses.

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.

The invention relates to the technical field of disease infection early warning, and discloses a male and male behavior AIDS infection internet self-assessment intervention system, which comprises a feature sequence generation module, which is used for collecting feature data of known AIDS virus infected persons and contact persons thereof to generate feature sequences; the social network graph construction module is used for constructing a social network graph; the social network graph splitting module is used for dividing the social network graph into a plurality of sub-graphs through a community detection algorithm based on modularity optimization; the risk level early warning module is used for inputting each sub-graph into an AIDS early warning model and outputting the risk level of a known AIDS virus infected person or a person in contact with the known AIDS virus infected person; the early warning measure generation module is used for generating early warning measures according to the risk levels; according to the AIDS early warning method, the social network graph is subjected to space-time analysis through the AIDS early warning model, the risk level of each person in the social network graph is automatically predicted, and the early warning measures are accurately generated according to the risk levels, so that the AIDS early warning efficiency is improved.

The invention discloses an efficient production process of an umbilical cord mesenchymal stem cell preparation in the field of stem cells, which comprises the following steps: S101, collection and separation of umbilical cord mesenchymal stem cells: under a sterile condition, separating Walton's jelly by adopting a tissue block culture method, taking out an umbilical cord from an umbilical cord bottle, transferring the umbilical cord into a sterile culture dish, and reserving a sample of a protective solution in the umbilical cord bottle for sterile detection; washing the umbilical cord with normal saline, cutting off two ends of the umbilical cord, discarding the umbilical cord, segmenting the umbilical cord for about 3-4cm, washing to remove blood, umbilical cord veins, two arteries and amniotic membranes, collecting the Walton's jelly, and transferring the Walton's jelly into a 50ml centrifugal tube; adding a small amount of the culture medium, cutting the Walton's gum into pieces with a size of about 1mm < 3 > by using scissors, and centrifugally washing for two times by using normal saline; the preparation produced by the invention is negative in detection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, syphilis antibody, cytomegalovirus and mycoplasma, and is high in extraction efficiency and convenient to popularize.

The application discloses a kind of chronic infectious disease digital people health management system construction method, it relates to AIDS nursing management technical field.Based on Triangle model, the management classification and characteristics of HIV patients are determined by latent profile and association rule analysis, and it is embedded into applet using agile development;Based on the basic nursing framework, the commonality and difference of patients in different levels are explored Care needs;Through the preliminary construction of AIDS hierarchical case management program by range review and focus group interview, the final draft is formed by revising and improving through written evaluation and field demonstration, and the well-constructed management program is embedded into a digital human interaction platform based on artificial intelligence.The application protects the privacy of patients, alleviates the shortage of medical human resources, meets the growing health needs of HIV patients, improves patient satisfaction and improves the quality of HIV care services.

The application provides a 4-quinazolinone derivative containing a benzene sulfonamide piperazine ketone and a preparation method and application thereof. The derivative has the structure shown in the following general formula I. The application further relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / HIV-2 capsid protein regulator in preparation of an anti-AIDS drug.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropteridine-6 (5H)-ketone skeleton compound as well as a preparation method and application thereof. The dihydropteridine-6 (5H)-ketone skeleton compound disclosed by the invention is an HIV-1 (Human Immunodeficiency Virus-1) non-nucleoside reverse transcriptase inhibitor; the invention also comprises pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in preparation of related drugs for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

Provided are membrane fusion inhibitors, derivatives thereof, pharmaceutical compositions thereof, and pharmaceutical uses thereof for inhibiting HIV and drug-resistant strains thereof.

The invention discloses an application of a UFMylation regulator in preparation of a medicine for resisting HIV (Human Immunodeficiency Virus) infection. According to the application disclosed by the invention, through in-vivo and in-vitro pharmacodynamic experiments, the inhibition effect of a UFMylation regulator, namely a UFSP2 inhibitor Compond-8, on an HIV (Human Immunodeficiency Virus) is evaluated. Experimental results show that the Compound 8 can significantly inhibit the replication of MT-4 cells, primary CD4 + T cells and HIV viruses in mice, can still maintain low virus load after drug withdrawal, has no obvious influence on the proliferation of normal cells and the weight of mice, and has a good anti-HIV infection effect and high safety. The invention reveals that the Compound 8 effectively inhibits HIV-1 replication for the first time, prompts that the Compound 8 can be used as a candidate drug of an HIV-1 treatment drug, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of HIV infection resistance.

Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and / or L-GP130. HIL-6 or L-GP130 continuous overexpression / conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS.

The invention discloses a method for constructing a model for performing treatment outcome grouping on AIDS (acquired immune deficiency syndrome) and phthisis patients and application of the method. The invention provides a method for constructing a model for performing anti-tuberculosis treatment outcome grouping on AIDS (Acquired Immune Deficiency Syndrome) and pulmonary tuberculosis patients, which comprises the following steps of: taking five specific index data of known AIDS and pulmonary tuberculosis patient groups with different anti-tuberculosis treatment outcomes as training samples; training a model for performing anti-tuberculosis treatment outcome grouping on the AIDS and pulmonary tuberculosis patients; the five specific indexes are CAR, extrapulmonary tuberculosis, other pulmonary infections, lung cavities and CD4 + T lymphocyte count. According to the method, clinical doctors can quickly identify AIDS and tuberculosis patients with high treatment failure risk, personalized management is carried out on the AIDS and tuberculosis patients, the method is of great importance to reduction of the occurrence rate of retreatment and drug-resistant tuberculosis, and a new strategy is provided for precise treatment.

The invention relates to an application of tanshinone I in preparation of a medicine for treating AIDS (Acquired Immune Deficiency Syndrome), and a tanshinone I compound is used for preparing the medicine for treating the AIDS and is applied to treatment of the AIDS. The Tanshinone I compound can significantly reduce the efficiency of programmed ribosome frameshift when the mRNA of HIV-1 translates a Gag-Pol fusion protein, so that the translation efficiency of the Pol protein is greatly reduced, thereby causing the ratio imbalance of Gag and Pol in cells, causing the virus not to be effectively packaged, and finally causing the sharp reduction of the yield of the virus, and having a good anti-HIV effect.

To provide a therapeutic or prophylactic vaccine for HIV disease.SOLUTION: A composition for delivering an antigen-expression system is provided, wherein the antigen-expression system comprises a vector backbone comprising a chimpanzee adenovirus vector, which is optionally a ChAdV68 vector, or an alphavirus vector, which is optionally a Venezuelan equine encephalitis virus vector, wherein the vector backbone comprises at least one HIV MHC class I antigen-encoding nucleotide sequence comprising an MHC class I epitope-encoding nucleotide sequence, wherein optionally the MHC class I epitope-encoding nucleotide sequence encodes an MHC class I epitope comprising at least one HIV epitope selected from the group consisting of the specified sequences.SELECTED DRAWING: Figure 34

The application provides a complex tablet of darunavir and cobicistat and a preparation method thereof, and the preparation method is as follows: darunavir ethanolate, part of a first disintegrant and a first lubricant are put into a dry granulator, granulation and whole granulation are carried out to obtain dry granules; hydroxypropyl methyl cellulose and proper water are mixed to form a binder solution, the dry granules and the rest of the first disintegrant are mixed, the binder solution is sprayed, and wet granulation is carried out, drying and whole granulation are carried out to obtain wet granules; the wet granules, silica loaded with cobicistat, a second disintegrant and a filler are mixed until uniform, then sieved, and a second lubricant is added and mixed again; tabletting is carried out, and then film coating is carried out. The application combines darunavir and cobicistat to prepare a medicine, reduces drug resistance caused by single drug use, and provides more choices for AIDS patients. In addition, the complex tablet can improve the content of darunavir.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

This application relates to the field of biomedicine and discloses the use of EN219 in the preparation of drugs for preventing and treating AIDS. This application has confirmed that EN219 can promote the functions of innate immune cells, break through the immune escape strategy of HIV, and can inhibit the replication of HIV in immune cells. To a certain extent, it overcomes the drawback of high compliance of traditional AIDS treatment drugs, discovers a new host drug target, and has a brand-new application prospect.

The invention provides a compound containing an indoleacetamide-fluorophenylalanine-hydroxyproline structure as well as a preparation method and application of the compound. The derivative has a structure as shown in a general formula I. The invention also relates to a preparation method of the compound and application of the compound as an HIV-1 capsid protein degradation agent in preparation of anti-AIDS drugs. # imgabs0 #

The invention discloses a method for screening antiviral targets by targeting virus DNA (deoxyribonucleic acid). The method comprises the following steps: respectively obtaining effective sgRNA (single guide ribonucleic acid) sequences targeting key DNA regions of varicella zoster virus, herpes simplex virus type I and Carbosi sarcoma related herpes virus; carrying out co-transfection on plasmids containing virus DNA and dCas9-sgRNA, and respectively carrying out immunoprecipitation enrichment on DNA of targeted varicella zoster virus, herpes simplex virus type I and Carbosi sarcoma related herpes virus to screen proteins for regulating virus replication; and identifying the protein by mass spectrum, and verifying that the method is also suitable for DNA screening of targeted human immunodeficiency virus to regulate and control the protein replication of the virus, so that the method for screening the protein replication of the virus by targeted virus DNA is established.

The application of the deubiquitinase to the immune reconstitution incomplete prediction target of the AIDS patient comprises the following steps: identifying that the ubiquitinase is YOD1 and has obvious interaction with HIV virus protein Nef; identifying that the YOD1 stabilizes the HIV auxiliary protein Nef through the protein level instead of the RNA level; identifying that the YOD1 can prolong the half-life period of the HIV auxiliary protein Nef; the YOD1 is identified to enhance the expression level of Nef in virus particles of an HIV NL4-3 clone strain by reducing the ubiquitination of the Nef protein of HIV-1 (Human Immunodeficiency Virus 1) and influence the ubiquitination of the K6 site of the Nef protein; identifying that YOD1 inhibits ubiquitination of Nef protein and stabilizes the Nef protein; yOD1 is identified to be in positive correlation with Nef under the HIV infection condition, and the positive correlation is increased along with the increase of the infection dose or the infection time; it is identified that YOD1 promotes virus replication by stabilizing the Nef protein level and aggravates loss of CD4 + T cells, and the expression level of YOD1 is in positive correlation with immune imperfection of an HIV-1 infected person; it is identified that the vitamin C can effectively lower the expression level of YOD1 and Nef protein, and then the virus virulence is reduced.

Provided in the present invention are novel compounds, a composition thereof, a preparation method therefor and the use thereof. The compounds (I) and the composition thereof of the present invention have a significant anti-human immunodeficiency virus effect, and have significantly improved in-vivo bioavailability.